2024
Impact of Self-Identified Race on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients Receiving Induction Therapy with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)
Joseph N, Gupta S, Kaufman J, Dicamillo S, Roberts D, Gupta V, Hofmeister C, Dhodapkar M, Lonial S, Nooka A. Impact of Self-Identified Race on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients Receiving Induction Therapy with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd). Blood 2024, 144: 7870-7870. DOI: 10.1182/blood-2024-211988.Peer-Reviewed Original ResearchNewly diagnosed myelomaD-RVdBlack patientsStatistically significant differenceInduction therapyR-ISSOverall survivalMedian ageInternational Myeloma Working Group Uniform Response CriteriaWhite patientsImproved depth of responsePresence of extramedullary diseaseNewly diagnosed multiple myelomaResponse rateMedian overall survivalR-ISS-3Effective induction regimenHigh-risk featuresStem cell transplantationDepth of responseSignificant differenceClinical trial findingsStandard of careHigh-risk classificationMedian PFS
2023
Efficacy of D-RVD Vs RVD Among t(11;14) Patients with Newly Diagnosed Myeloma
Kaufman J, Joseph N, Gupta V, Dicamillo S, Roberts D, Hofmeister C, Dhodapkar M, Nooka A, Lonial S, Boise L. Efficacy of D-RVD Vs RVD Among t(11;14) Patients with Newly Diagnosed Myeloma. Blood 2023, 142: 4699. DOI: 10.1182/blood-2023-181783.Peer-Reviewed Original ResearchStandard-risk patientsVGPR ratesRisk patientsPart of inductionInduction therapyMyeloma patientsNDMM patientsInternational Myeloma Working Group Uniform Response CriteriaStage 3 patientsCombination of lenalidomideHigh-risk patientsPhase 3 studyCohort of patientsUniform response criteriaDistinct clinical presentationsFree light chainsInstitutional review boardLenalidomide maintenanceMedian OSMedian PFSRVD inductionLast followClinical characteristicsOverall survivalPatient characteristicsA Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study
Nooka A, Joseph N, Gupta V, Hofmeister C, Dhodapkar M, Burton B, Ahmed H, Linton D, Cortoos A, Lin T, Labotka R, Noga S, Kaufman J, Lonial S. A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study. Blood 2023, 142: 4764. DOI: 10.1182/blood-2023-190871.Peer-Reviewed Original ResearchProgression-free survivalArm BPeripheral neuropathyInduction therapyPrimary endpointOverall survivalAutologous stem cell transplantGrade 3/4 peripheral neuropathyRandomized phase 2 studyTransplant-eligible myeloma patientsRandomized phase II studySecondary primary malignanciesTransplant-eligible patientsTransplant-ineligible patientsAdverse event profilePhase 2 studyPhase II studyStem cell transplantWinship Cancer InstituteInhibitor combination therapyStem cell collectionRegular clinical practiceHigh response rateMultiple myeloma studyMedian follow